How one scientists determination made Novo Nordisk an obesity-drug powerhouse Lotte Bjerre Knudsen was still getting used to all the empty benches in her lab when she ran into a tall man with black wide-framed glasses in the hallway: Mads Krogsgaard Thomsen, the new head of research at the Danish drugmaker Novo Nordisk, and her new boss
Take with water or as directed
The data is striking: in a Phase 2 trial published in the New England Journal of Medicine, the highest doses produced an average ~24% body-weight reduction at 11 months more than any currently approved weight-loss drug (American Diabetes Association)
The key conclusions included that lower doses of anti-obesity medications are working well for a majority of patients, and that insurance coverage is the most important factor in the decision-making process
I always liked looking fresh-looking with a tan." Eagle was initially delighted with how well the DIY darkener did the trick
[DOI] [PubMed] [Google Scholar] 42.van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH